

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 30, 2011 (August 30, 2011)

---

HARRIS & HARRIS GROUP, INC.

---

(Exact name of registrant as specified in its charter)

**New York**  
(State or other jurisdiction of  
incorporation)

**0-11576**  
(Commission File  
Number)

**13-3119827**  
(IRS Employer  
Identification No.)

---

**1450 Broadway**  
**New York, New York 10018**  
(Address of principal executive offices and zip code)

**(212) 582-0900**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

Harris & Harris Group, Inc. (NASDAQ: TINY) noted today that Metabolon, Inc. announced it has successfully raised \$13.1 million in a Series D round of financing. New investor, Keating Capital, Inc., joined existing investors, Harris & Harris Group, Sevin Rosen Funds, Aurora Funds, Syngenta Ventures, Fletcher Spaght and Fulcrum Financial Partners in the round. Harris & Harris Group participated in the Series D financing with an investment of \$1.5 million. This investment brings Harris & Harris Group's total investment at cost in Metabolon to \$6 million.

The Company's press release is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

- (a) Not applicable.
- (b) Not applicable.
- (c) Not applicable.
- (d) Exhibits.

**Exhibit No.**

**Description**

99.1

Press Release dated August 30, 2011

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 30, 2011

HARRIS & HARRIS GROUP, INC.

By: /s/ Daniel B. Wolfe  
Daniel B. Wolfe  
President

---

**EXHIBIT INDEX**

**Exhibit No.**

**Description**

99.1

Press Release dated August 30, 2011

---

**PRESS RELEASE**

**HARRIS & HARRIS GROUP, INC.®**  
**1450 BROADWAY, 24<sup>TH</sup> FLOOR**  
**NEW YORK, NY 10018**

**FOR IMMEDIATE RELEASE**

**AUGUST 30, 2011**

**CONTACT: DANIEL B. WOLFE**

**TEL. NO. (212) 582-0900**

**Harris & Harris Group Notes Metabolon Financing**

Harris & Harris Group, Inc. (NASDAQ: TINY) notes that Metabolon, Inc. announced it has successfully raised \$13.1 million in a Series D round of financing. New investor, Keating Capital, Inc., joined existing investors, Harris & Harris Group, Sevin Rosen Funds, Aurora Funds, Syngenta Ventures, Fletcher Spaght and Fulcrum Financial Partners in the round. The proceeds from this financing are expected to support further growth of the company's global biochemical profiling services and ongoing development of its oncology diagnostic product portfolio. Harris & Harris Group participated in the Series D financing with an investment of \$1.5 million. This investment brings Harris & Harris Group's total investment at cost in Metabolon to \$6 million. Metabolon's press release may be accessed at [http://www.metabolon.com/news/PressReleases.aspx?year=2011&open=082911#082911\\_span](http://www.metabolon.com/news/PressReleases.aspx?year=2011&open=082911#082911_span).

Harris & Harris Group is a publicly traded venture capital company that invests in nanotechnology and microsystems. Detailed information about Harris & Harris Group and its holdings can be found on its website at [www.HHVC.com](http://www.HHVC.com).

This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2010, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The references to the websites [www.HHVC.com](http://www.HHVC.com) and [www.metabolon.com](http://www.metabolon.com) have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Harris & Harris Group is not responsible for the content of third party websites.

---